Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 1 de 1
1.
Leuk Res ; 99: 106463, 2020 12.
Article En | MEDLINE | ID: mdl-33130331

BACKGROUND: Vancomycin-resistant enterococcus (VRE) is an infectious agent that can increase morbidity and mortality, especially in patients with neutropenia in haematology departments. We analysed VRE infections and mortality rates among VRE colonized patients with acute leukaemia, defined predisposing risk factors for infection and mortality, and investigated the influence of daptomycin or linezolid treatment on mortality. PATIENTS-METHODS: We included 200 VRE colonized adult acute leukaemia patients with febrile neutropenia between January 2010 and January 2016. Data were collected from electronic files. RESULTS: There were 179 patients in the colonized group, and 21 patients in the infected group. Enterococcus faecium (van A) was isolated from all patients. The infection rate was 10.5 %, and the types of infections noted were as follows: bloodstream (n = 14; 66.7 %), skin and soft tissue (n = 3; 14.3 %), urinary (n = 2; 9.5 %), and others (9.5 %). In the multivariate logistic regression analysis, exposure to invasive procedures, coinfection status, and >15 days of VRE positivity were independent risk factors for VRE infections. In hospital mortality rates were 57.1 % in the infected group, and 9.5 % in the colonized group (p < 0.001). Older age, female gender, absolute neutropenia, and coinfection status were statistically significant predictor of survival. CONCLUSION: Vancomycin-resistant enterococcus infections are associated with high morbidity and mortality in haematology patients with neutropenia. Clinicians should be aware of predisposing risk factors for VRE infection to avoid unfavourable outcomes. We believe that larger studies are necessary regarding the influence of treatment with daptomycin and linezolid.


Enterococcus faecium/drug effects , Febrile Neutropenia/complications , Gram-Positive Bacterial Infections/etiology , Leukemia, Myeloid, Acute/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Vancomycin Resistance , Adult , Age Factors , Aged , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/etiology , Bacteremia/microbiology , Cross Infection/drug therapy , Cross Infection/etiology , Cross Infection/microbiology , Cross Infection/mortality , Daptomycin/therapeutic use , Enterococcus faecium/isolation & purification , Female , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/mortality , Hospital Mortality , Humans , Kaplan-Meier Estimate , Linezolid/therapeutic use , Male , Middle Aged , Proportional Hazards Models , Retrospective Studies , Risk Factors , Sex Factors , Soft Tissue Infections/drug therapy , Soft Tissue Infections/etiology , Soft Tissue Infections/microbiology , Turkey/epidemiology , Urinary Tract Infections/drug therapy , Urinary Tract Infections/etiology , Urinary Tract Infections/microbiology , Vancomycin/pharmacology , Vancomycin/therapeutic use
...